Showing 3511-3520 of 5646 results for "".
- The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Monthshttps://modernod.com/news/the-european-commission-ec-approves-eylea-8-mg-for-extended-treatment-intervals-of-up-to-6-months/2482867/The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously
- Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lenshttps://modernod.com/news/ocumetics-initiates-first-in-human-study-of-accommodating-intraocular-lens/2482866/Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens. Designed to mimic the natural focusing ability of the youthful hu
- Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-presents-positive-interim-phase-2-results-for-subcutaneous-migaldendranib-treatment-for-dme-and-wet-amd/2482864/Ashvattha Therapeutics announced interim results from its ongoing phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The data were presented at the MaculArt Meeting, June 29–July 1, 2025
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr
- Alcon Introduces Clareon PanOptix Pro in Canadahttps://modernod.com/news/alcon-introduces-clareon-panoptix-pro-in-canada/2482857/Alcon announced the approval of Clareon PanOptix Pro IOL in Canada. According to Alcon, PanOptix Pro leverages the company's proprietary 'ENLIGHTEN NXT' optical technology, which delivers the lowest light scatter and highest reported light utilization of
- New York Eye and Ear Infirmary of Mount Sinai Opens First Comprehensive Center for Refractive Solutions in New Yorkhttps://modernod.com/news/new-york-eye-and-ear-infirmary-of-mount-sinai-opens-first-comprehensive-center-for-refractive-solutions-in-new-york/2482855/The New York Eye and Ear Infirmary of Mount Sinai (NYEE) has announced the launch of the Center for Refractive Solutions, a facility dedicated to comprehensive vision correction services. Located at 310 East 14th Street in Lower Manhattan, the newly renovated
- Sightview Appoints Tycene Fritcher as CEOhttps://modernod.com/news/sightview-appoints-tycene-fritcher-as-ceo/2482850/Ophthalmic Electronic health record (EHR) provider Sightview announced that Tycene Fritcher has been appointed Chief Executive Officer. Ms. Fritcher brings more than two decades of leadership experience in healthcare IT, including tenures at Nextech, Avizia, and Am
- Heidelberg Engineering Launches ZinserLab Innovation Hub to Accelerate Imaging Innovation in Eye Carehttps://modernod.com/news/heidelberg-engineering-launches-zinserlab-innovation-hub-to-accelerate-imaging-innovation-in-eye-care/2482848/Heidelberg Engineering announced the launch of the ZinserLab, an innovation hub that aims to accelerate the development of imaging technologies with clinical value for eye care. The hub is named in honor of Dr. Gerhard Zinser, the
- Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Datahttps://modernod.com/news/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data/2482846/Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a
- Gore Launches 0.5 mL Silicone-Free Gore Improject Plunger for Ophthalmic Pre-Filled Syringeshttps://modernod.com/news/gore-launches-05-ml-silicone-free-gore-improject-plunger-for-ophthalmic-pre-filled-syringes/2482843/W. L. Gore & Associates announced the commercial launch of the 0.5 mL silicone-free Gore Improject syringe plunger. The new offering, made within the company's PharmBIO business, is designed for prefilled syringes used in various applications, including ophthalmic intr